Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01424033 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial for CTD-ILD Treatment
A Phase 2 study, sponsored by University of Michigan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01424033 is a Phase 2 study that was terminated before completion, run by University of Michigan. The registered enrollment target is 5 participants.
The verdict
NCT01424033, a Phase 2 study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
Interventions
- DRUG N-Acetylcysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01424033
The ClinicalTrials.gov registry entry for NCT01424033 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-Acetylcysteine is the first listed.
NCT01424033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01424033 about?
NCT01424033 is a clinical study titled "A Clinical Trial for CTD-ILD Treatment". The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
What is the current status of trial NCT01424033?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2011-12.
What interventions are being tested in trial NCT01424033?
The interventions under investigation include: N-Acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT01424033?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.